Statin use related to occurrence of daptomycin-related rhabdomyolysis: Study
Japan: Statin use is associated with daptomycin (DAP)-related rhabdomyolysis occurrence, show mixed approach combining a meta-analysis and disproportionality analysis. The appropriate use of DAP and statins should, therefore, be performed with careful consideration of their safety. The study was published in the journal Clinical Infectious Diseases on 09 March 2022.
There is a growing concern on the link between combined use of DAP and statins and the occurrence of musculoskeletal adverse events (MAEs), but this remains controversial. Masayuki Chuma, Tokushima University Hospital, Tokushima, Japan, and colleagues, therefore, aimed to clarify the association between statin use and DAP-related MAEs.
For this purpose, the researchers used a mixed approach combining two methodologies. First, a meta-analysis was conducted to examine the effects of statin use on DAP-related MAEs. Secondly, a disproportionality analysis was conducted using the FDA Adverse Events Reporting System (FAERS) to further confirm the results of the meta-analysis and to examine the effect of each type of statin on DAP-related MAEs in a large population.
The study revealed the following findings:
- In the meta-analysis, statin use significantly increased the incidence of DAP-related rhabdomyolysis (odds ratio [OR]: 3.83) but not DAP-related myopathy (OR: 1.72).
- In the disproportionality analysis using the FAERS, the use of statin significantly increased the reporting OR (ROR) for DAP-related myopathy (ROR: 5.69) and rhabdomyolysis (ROR: 5.77).
- Atorvastatin, rosuvastatin, and simvastatin all increased the incidence of DAP-related myopathy and rhabdomyolysis.
"Findings showed that statin use was associated with the occurrence of DAP-related rhabdomyolysis. The appropriate use of statins and DAP should be performed with careful consideration of its safety," wrote the authors.
Reference:
Masayuki Chuma, Aki Nakamoto, Takashi Bando, Takahiro Niimura, Yutaka Kondo, Hirofumi Hamano, Naoto Okada, Mizuho Asada, Yoshito Zamami, Kenshi Takechi, Mitsuhiro Goda, Koji Miyata, Kenta Yagi, Toshihiko Yoshioka, Yuki Izawa-Ishizawa, Hiroaki Yanagawa, Yoshikazu Tasaki, Keisuke Ishizawa, Association between statin use and daptomycin-related musculoskeletal adverse events: A mixed approach combining a meta-analysis and a disproportionality analysis, Clinical Infectious Diseases, 2022;, ciac128, https://doi.org/10.1093/cid/ciac128
KEYWORDS: daptomycin, statin, musculoskeletal adverse event, meta-analysis, disproportionality analysis, Masayuki Chuma, Clinical Infectious Diseases, rhabdomyolysis
